Evidence map›Paper›PMID 30032478›Full record

ArticleIrish journal of medical science2019

The changing cost of breast cancer care: lessons from a centralised modern cancer centre.

Doireann P Joyce, Ciaran O'Neill, Helen M Heneghan, Catherine Curran, Kevin Barry, Karl Sweeney, Carmel Malone, Ray McLaughlin, Michael J Kerin

Abstract read
PubMed Publisher
In one paragraph

Article in Irish journal of medical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Doireann P JoyceDiscipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland. doireann.joyce@gmail.com.
Ciaran O'NeillJ.E. Cairnes School of Business & Economics, National University of Ireland Galway, Galway, Ireland.
Helen M HeneghanDiscipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.
Catherine CurranDiscipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.
Kevin BarryDiscipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.
Karl SweeneyDiscipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.
Carmel MaloneDiscipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.
Ray McLaughlinDiscipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.
Michael J KerinDiscipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe cost of new cancer technologies has been the subject of intense debate in recent years. There have been significant advances in therapeutic techniques for breast cancer over the past 20 years. This has been accompanied by the concentration of services in designated cancer centres. The aim of this study was to examine the changing cost of breast cancer management over an 18-year period and identify factors underlying this.

methodsWe use breast cancer services data from Galway University Hospital in 1995-1996, 2005-2006 and 2011-2012 to examine the changing pattern of care costs and survival.

resultsThe number of patients treated for breast cancer rose from 200 in 1995-1996, to 411 in 2005-2006 and 563 in 2011-2012. Two-year survival rose in line with national figures from 84 to 89.78 and 92.07%, in the three-time periods respectively. Adjusting for inflation, the average cost per patient rose from €14,710 (95% C.I., €13,398 to €16,022) in 1995-1996 to €30,405 (95% C.I., €38,620 to €32,189) in 2005-2006, before falling to €14,458 (C.I., €13,343 to €15,572) in 2011-2012. We found significant changes in the pattern of costs, with some rising in relative and absolute terms while others fell as new therapies became available and/or moved off patent.

conclusionWithin an evolving context where services are centralised, new therapies emerge and subsequently come off patent, our understanding of the value of cancer therapies continues to evolve. This has important implications for the evaluation of new therapies and broader policy initiatives in this area.

Indexed as

Breast NeoplasmsCancer Care FacilitiesCost-Benefit AnalysisFemaleHumansMiddle AgedBreastBreast cancerBreast surgeryHealth economicsOncology

Identifiers

PMID30032478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.